New Key Statistics Module, Z-Score and F-Score
NAS:RIGL Key Ratios
| Market Cap $ M | 210.49 |
| Enterprise Value $ M | 214.13 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | -- |
| Price/Sales | 1.79 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 116.00 |
| EPS (TTM) $ | -0.14 |
| Beneish M-Score | -3.46 |
| 10-y EBITDA Growth Rate % | 21.00 |
| 5-y EBITDA Growth Rate % | 22.80 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -11.75 |
| EV-to-EBITDA | -12.61 |
| PEG | -- |
| Shares Outstanding M | 175.40 |
| Net Margin (%) | -21.47 |
| Operating Margin % | -17.53 |
| Pre-tax Margin (%) | -21.47 |
| Quick Ratio | 1.76 |
| Current Ratio | 1.86 |
| ROA % (ttm) | -20.65 |
| ROE % (ttm) | -- |
| ROIC % (ttm) | -42.22 |
| Dividend Yield % | -- |
| Altman Z-Score | -14.99 |
RIGL Number of Guru Trades
RIGL Volume of Guru Trades
Gurus Latest Trades with NAS:RIGL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:RIGL is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Rigel Pharmaceuticals Inc Insider Transactions
No Available Data
News about NAS:RIGL
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers